<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631953</url>
  </required_header>
  <id_info>
    <org_study_id>2018-05</org_study_id>
    <secondary_id>RCAPHM18_0015</secondary_id>
    <nct_id>NCT03631953</nct_id>
  </id_info>
  <brief_title>Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas</brief_title>
  <acronym>ALTREM</acronym>
  <official_title>Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy constitute an
      unmet pharmaceutical need in neurooncology, leading to a fatal issue within a few months.
      Grade II-III meningiomas progression-free survival (PFS) 6 is at 10-15%. Median PFS grade III
      meningioma is approximate 3 years.

      Alpelisib is a well-tolerated Phosphoinositide 3-kinase α (Pi3Kα) specific inhibitor.
      However, phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR)
      inhibition does not induce apoptosis in vitro and induces an antiproliferative effect without
      any radiologic response in most treated patients.

      Trametinib, a mekinist (MEK) inhibitor is currently used in combined treatment for recurrent
      melanomas in clinical practice with a good clinical tolerance at 1-2 mg daily. In vitro, on
      meningioma primary cell culture, Trametinib induces cell apoptosis via caspase activity.

      These results strongly suggest the relevance to combine Alpelisib and Trametinib in
      aggressive and recurrent meningiomas.

      Alpelisib and Trametinib combination has not been studied to date, despite each drugs have
      been separately studied in phase 3.

      Multicenter, open label, dose-finding phase I study of Alpelisib in combination with
      Trametinib administered at a fixed dose (1.5 mg daily), both drugs will be administered
      daily. Starting dose of Alpelisib will be 160mg/day and will be increased to 200mg/day or
      decreased to 120mg/day depending of grade 3-4 adverse events occurrence, to determine maximal
      tolerated dose (MTD) and recommended dose.

      Primary Objective is to determine the safety profile and tolerability of Alpelisib and
      Trametinib given in combination in patients with aggressive and refractory meningiomas in
      terms of Dose-Limiting Toxicities (DLT, assessed during cycle 1).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) rate of combination Alpelisib and Trametinib</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate adverse events graded (toxicity) according to National Cancer Institute's Common Toxicity Criteria (version 4.0).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Meningioma</condition>
  <arm_group>
    <arm_group_label>Alpelisib in combination with Trametinib administered</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A panel of 3 doses of Alpelisib could be tested in combination with fixed dose of Trametinib (1.5 mg every day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib administered at a fixed dose (1.5 mg daily)</description>
    <arm_group_label>Alpelisib in combination with Trametinib administered</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpelisib</intervention_name>
    <description>A panel of 3 doses of ALPELISIB could be tested</description>
    <arm_group_label>Alpelisib in combination with Trametinib administered</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Therapeutic biomarkers</description>
    <arm_group_label>Alpelisib in combination with Trametinib administered</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>A MRI with contrast will be performed before treatment start. Assessment of tumor growth.</description>
    <arm_group_label>Alpelisib in combination with Trametinib administered</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven meningioma grade I, II and III

          -  Progression is defined as growing meningiomas on 2 different Magnetic Resonance
             Imaging (MRI) 3 to 6 months apart

          -  Patients must have failed surgery, and not amenable to a new curative intended surgery

          -  Patients must have failed radiotherapy and/or radiosurgery

          -  Patients who have given their written consent

          -  No contra indication to Alpelisib and Trametinib

          -  No receiving other investigational agents

          -  Written informed consent

          -  Adequate bone marrow function

          -  Adequate liver function as shown by

          -  Adequate renal function

        Exclusion Criteria:

          -  Contra indication to Alpelisib and Trametinib

          -  Women of child-bearing age who are using no effective means of contraception

          -  Pregnant or breast-feeding women

          -  Patients receiving other investigational agents

          -  Known intolerance or hypersensitivity to Alpelisib and Trametinib

          -  Uncontrolled diabetes mellitus

          -  Patients who have any severe and uncontrolled medical condition

          -  Patients receiving chronic treatment with immunosuppressives

          -  Patients with a known history of HIV seropositivity

          -  Patients who have a history of another primary malignancy less than or equal to 3
             years, with

          -  the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Oliver ARNAUD, Director</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas GRAILLON, PH</last_name>
    <phone>491385545</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.graillon@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier CHINOT, PU-PH</last_name>
    <phone>491385545</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.chinot@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GRAILLON, PH</last_name>
      <phone>491385545</phone>
      <phone_ext>+33</phone_ext>
      <email>thomas.graillon@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier CHINOT, PU-PH</last_name>
      <phone>491385545</phone>
      <phone_ext>+33</phone_ext>
      <email>olivier.chinot@ap-hm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas GRAILLON, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

